Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 4/21/2016 |
| Start Date: | March 2015 |
mTOR kinase is part of the mTORC1 complex that promotes cap-dependent protein translation,
and part of the mTORC2 complex that activates AKT. Everolimus (Afinitor) is an allosteric
inhibitor of mTOR that suppresses mTORC1 activity. Everolimus is FDA-approved for the
treatment of ER+/HER2- breast cancer (in combination with exemestane), renal cell carcinoma,
subependymal giant cell astrocytoma (SEGA), and neuroendocrine tumors of pancreatic origin
(PNET), and is currently being tested in ongoing clinical studies in other indications.
While everolimus-based therapies elicit anti-cancer effects, most cancers ultimately
progress and exhibit everolimus resistance. This study will evaluate genetic mechanisms of
resistance to everolimus.
and part of the mTORC2 complex that activates AKT. Everolimus (Afinitor) is an allosteric
inhibitor of mTOR that suppresses mTORC1 activity. Everolimus is FDA-approved for the
treatment of ER+/HER2- breast cancer (in combination with exemestane), renal cell carcinoma,
subependymal giant cell astrocytoma (SEGA), and neuroendocrine tumors of pancreatic origin
(PNET), and is currently being tested in ongoing clinical studies in other indications.
While everolimus-based therapies elicit anti-cancer effects, most cancers ultimately
progress and exhibit everolimus resistance. This study will evaluate genetic mechanisms of
resistance to everolimus.
Inclusion Criteria:
1. Treatment with everolimus (as a single-agent or in combination) for any malignancy
for ≥3 months.
2. A- Patients who are scheduled to undergo a clinically indicated tumor biopsy (as
standard of care, or as part of another study) within 5 years following cancer
progression on everolimus are eligible.
B- Patients who already had such a biopsy procedure performed are eligible. Tumors
biopsied shortly after progression on everolimus are strongly preferred.
3. Excess tumor tissue from biopsy must be available for molecular analysis. This will
include tumor tissue sufficient to make ≥5 five-micron sections; more tumor tissue is
preferred.
4. Patients currently seen at Dartmouth-Hitchcock Medical Center must be capable and
willing to provide informed written consent for study participation. Patients who are
no longer seen at DHMC will not be consented for use of archived tissues and data.
5. For patients currently seen at Dartmouth-Hitchcock Medical Center, patients must be
willing to provide an extra 10-20 mL of blood during a routine, clinically indicated
blood draw procedure.
Exclusion Criteria:
We found this trial at
1
site
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
